Related Experiment Video
Updated: Jun 3, 2026
08:19
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
Published on: June 22, 2020
Increased plasma myostatin in heart failure.
Damien Gruson1, Sylvie A Ahn, Jean-Marie Ketelslegers
1Department of Laboratory Medicine, Cliniques Universitaires St-Luc, Tour Rosalyn Franklin, Avenue E. Mounier, Brussels, Belgium. damien.gruson@uclouvain.be
European Journal of Heart Failure
|April 7, 2011
Summary
Myostatin (Mstn) levels are elevated in congestive heart failure (CHF) patients and correlate with heart failure severity biomarkers. This study confirms Mstn activation in heart failure.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
Background:
- Myostatin (Mstn), a TGF-β family member, regulates skeletal muscle growth.
- Mstn has been identified as a regulator of cardiomyocyte growth.
- Congestive heart failure (CHF) involves complex neurohormonal dysregulation.
Purpose of the Study:
- To measure plasma Mstn concentrations in CHF patients.
- To evaluate the relationship between Mstn levels and other CHF-related neurohormones.
- To assess Mstn's role in the pathophysiology of heart failure.
Main Methods:
- Competitive immunoassay used to measure Mstn plasma concentrations.
- Study included 76 CHF patients and 60 healthy controls.
- Measured neurohormones included NT-proANP, BNP, NT-proBNP, and Big ET-1.
Main Results:
- Plasma Mstn concentrations were significantly higher in CHF patients compared to controls (63.0 vs. 43.0 ng/mL; P < 0.001).
- Mstn levels positively correlated with NT-proANP, BNP, NT-proBNP, and Big ET-1 in CHF patients.
- No significant correlations were found between Mstn and age or creatinine.
Conclusions:
- Plasma Mstn concentrations are significantly increased in patients with CHF.
- Mstn levels correlate with established biomarkers of heart failure severity.
- The findings confirm the activation of Mstn in the context of heart failure.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...